A systemic approach to SjD At Johnson & Johnson, we are currently exploring an investigational therapy for the treatment of SjD. This research is reflective of Johnson & Johnson’s ongoing commitment to better assess the pathophysiology of autoantibody-driven diseases and identify and target their underlying cause. Prioritizing patient perspectives with…
Sponsored Content
Recent Posts
- Blood molecule may offer new way to detect and track Sjögren’s disease
- A closer look at Sjögren’s disease: How Johnson & Johnson is driving patient-informed research
- Childhood-onset Sjögren’s can cause lasting damage to organs: Study
- Salivary duct treatment eases dry mouth in Sjögren’s disease: Study
- 4 genes linked to inflammatory cell death very active in Sjögren’s
- AI can see what doctors miss to accurately diagnose Sjögren’s
- Worse fatigue tied to more pain in people with Sjögren’s, study finds
- Dazodalibep therapy now in Phase 3 testing for Sjögren’s disease
- Sjögren’s treatment ianalumab shows rapid disease relief in trials
- Sjögren’s patients on nipocalimab report less pain, dryness in trial